These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

423 related items for PubMed ID: 10370911

  • 21. Contemporary Options for the Management of Motor Complications in Parkinson's Disease: Updated Clinical Review.
    Cabreira V, Soares-da-Silva P, Massano J.
    Drugs; 2019 Apr; 79(6):593-608. PubMed ID: 30905034
    [Abstract] [Full Text] [Related]

  • 22. Impaired absorption of oral levodopa: a major cause for response fluctuations in Parkinson's disease.
    Djaldetti R, Ziv I, Melamed E.
    Isr J Med Sci; 1996 Dec; 32(12):1224-7. PubMed ID: 9007159
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Interventions to achieve tonic exposure to levodopa: delaying or preventing the onset of motor complications.
    Luer MS.
    Pharmacotherapy; 1999 Nov; 19(11 Pt 2):169S-79S. PubMed ID: 10555945
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Optimizing pharmacotherapy: strategies to manage the wearing-off phenomenon.
    Tse W.
    J Am Med Dir Assoc; 2006 Sep; 7(7 Suppl 2):12-7. PubMed ID: 17948614
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Current strategies in the drug treatment of advanced Parkinson's disease--new modes of dopamine substitution.
    Schelosky L, Poewe W.
    Acta Neurol Scand Suppl; 1993 Sep; 146():46-9. PubMed ID: 8101415
    [Abstract] [Full Text] [Related]

  • 29. Drugs for Parkinson's disease.
    Treat Guidel Med Lett; 2013 Nov; 11(135):101-6. PubMed ID: 24165688
    [Abstract] [Full Text] [Related]

  • 30. Pharmacokinetic and pharmacodynamic considerations in management of motor response fluctuations in Parkinson's disease.
    Cedarbaum JM.
    Neurol Clin; 1990 Feb; 8(1):31-49. PubMed ID: 2181267
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Strategies for treating patients with advanced Parkinson's disease with disastrous fluctuations and dyskinesias.
    Stocchi F, Nordera G, Marsden CD.
    Clin Neuropharmacol; 1997 Apr; 20(2):95-115. PubMed ID: 9099462
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Long term motor complications of levodopa: clinical features, mechanisms, and management strategies.
    Thanvi BR, Lo TC.
    Postgrad Med J; 2004 Aug; 80(946):452-8. PubMed ID: 15299154
    [Abstract] [Full Text] [Related]

  • 36. Levodopa ethylester: a novel rescue therapy for response fluctuations in Parkinson's disease.
    Djaldetti R, Melamed E.
    Ann Neurol; 1996 Mar; 39(3):400-4. PubMed ID: 8602763
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Pharmacokinetic considerations for the use of levodopa in the treatment of Parkinson disease: focus on levodopa/carbidopa/entacapone for treatment of levodopa-associated motor complications.
    Müller T.
    Clin Neuropharmacol; 2013 Mar; 36(3):84-91. PubMed ID: 23673910
    [Abstract] [Full Text] [Related]

  • 39. Pharmacokinetics and pharmacodynamics of levodopa.
    Nutt JG.
    Mov Disord; 2008 Mar; 23 Suppl 3():S580-4. PubMed ID: 18781675
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.